Maximus slips after lowered FY2027 profit outlook
MMS•Maximus forecast FY2027 adjusted EPS of $7.50 to $8.00, below FY2026 adjusted EPS of $8.24, and reported lower revenue and free cash flow for FY2026. Its shares fell 5.4% in morning trading.
1. Outlook and results
Maximus forecast FY2027 adjusted EPS of $7.50 to $8.00, compared with FY2026 adjusted EPS of $8.24. The company reported FY2026 revenue of $5.23 billion, down from $5.43 billion in FY2025, and free cash flow of $69 million, compared with $366 million a year earlier. Maximus said strong performance across its clinical portfolio benefited the fourth quarter and is expected to moderate in FY2027.




